For Q3 FY2025, Compass Therapeutics reported no revenue and a net loss of $18.3 million, a 10.1% increase from the prior year. Operating loss was $20.3 million, up 13.0% year-over-year. Diluted EPS was -$0.10, improving 16.7% from the prior year.
•No revenue generated in Q3 FY2025.
•Net loss of $18.3 million, up 10.1% YoY.
•Operating loss of $20.3 million, up 13.0% YoY.
•Diluted EPS of -$0.10, improving 16.7% YoY.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company develops antibody-based therapeutics for the treatment of various human diseases in the United States.
The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Its portfolio also includes CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies, and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. Founded in 2014, the company is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology. Its lead candidate, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A, which are involved in angiogenesis and tumor vascularization. The company also has CTX-471, an IgG4 monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Additionally, its pipeline includes CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. These therapies are designed to treat various human diseases, primarily cancers.
Where is Compass Therapeutics (CMPX) listed and in which currency?
Compass Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CMPX. Its shares are traded in U.S. dollars (USD). The company is headquartered in Boston, Massachusetts, and operates primarily in the United States.
What sector and industry does Compass Therapeutics (CMPX) belong to?
Compass Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing antibody-based therapies for oncology. Biotechnology companies like Compass use biological processes and living organisms to create treatments, often targeting specific molecular pathways involved in diseases such as cancer.
Where is Compass Therapeutics (CMPX) headquartered and what markets does it serve?
Compass Therapeutics is headquartered in Boston, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its regional classification as 'us'. Its research and development activities are centered in the United States, and it focuses on developing therapies for patients with various human diseases, particularly cancers.
What are the main product candidates in Compass Therapeutics' (CMPX) pipeline?
Compass Therapeutics' pipeline includes several antibody-based therapeutics. The lead candidate is tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, which are key to angiogenesis and tumor vascularization. Another candidate is CTX-471, an IgG4 monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. The company also has CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1 checkpoint inhibitors, and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. These candidates are in clinical-stage development for oncology indications.